Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Dealmaking in 2009: A Look Back and A Glance Ahead

Executive Summary

This article was excerpted from "Top Device Stories of 2009: A Year of Economic Revival and Regulatory Risk," IN VIVO, January 2010.

You may also be interested in...



Device Tax, Health Reform Close To Reality As Conference Committee Meets

As the House and Senate work to meld their respective 2,000-page health care reform bills into a single politically viable plan, the device industry remains most intently focused on a mere seven pages of each: the device tax provisions

On-Q-ity Inc.

Formed by the 2009 merger of CELLective DX and DNA Repair Co., On-Q-ity Inc. is developing personalized molecular diagnostics for cancer. The start-up thinks that combining DNA repair biomarkers with its ability to capture and analyze circulating tumor cells provides a complete view of an individual patient's pending treatment options and allows for more patient-friendly monitoring of the treatment's progress. On-Q-ity is currently conducting large-scale trials analyzing the response of DNA repair mechanisms to breast cancer therapies, focusing particularly on the anthracycline class of drugs. Initial studies are based on tissue samples, but the company will begin trials with circulating tumor cells in various cancers later this year.

CDRH To Abandon Bad Precedents On Path To Predictable 510(k)s

FDA's device center wants to make the 510(k) process more predictable, but one of the first steps to accomplishing this is to break from what CDRH acknowledges are some questionable past decisions, according to a top Office of Device Evaluation official

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

MT035326

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel